grant
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 1 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025ASCVDAcetylsalicylic AcidAddressAmericanAntifibrinolysinsAntifibrinolytic AgentsAntifibrinolyticsAntisense AgentAntisense OligonucleotidesAortic StenosisAortic Valve StenosisApo Lp(a)AspirinAtherosclerosisAtherosclerosis Risk in CommunitiesAtherosclerotic Cardiovascular DiseaseAwardBiometricsBiometryBiostatisticsBlackBlack raceBleedingBlood PlasmaBlood PlateletsBlood SampleBlood specimenCVD preventionCardiologyCardiovascularCardiovascular Body SystemCardiovascular DiseasesCardiovascular Organ SystemCardiovascular systemClinicCohort StudiesCollaborationsConcurrent StudiesCountyDataDedicationsDevelopment PlansDiabetes MellitusDoseEC 3.4.21.7ElderlyEpidemiologic MethodologyEpidemiologic MethodsEpidemiologic research methodologyEpidemiologic research methodsEpidemiological MethodsEpidemiological TechniquesEpidemiologyEventFDA approvedFemale HealthFibrinolysesFibrinolysisFoundationsFundingGenesGenetic PolymorphismGoalsGrantGuidelinesHeartHeart VascularHemorrhageHistoryIndividualInstitutionInternal MedicineInvestigatorsIschemiaLDLLDL LipoproteinsLipidsLipoprotein (a)Lipoprotein Lp(a)LiteratureLow-Density LipoproteinsLp(a)Marrow plateletMeasuresMedicalMessenger RNAMethods EpidemiologyMethods in epidemiologyMulti-Ethnic Study of AtherosclerosisParticipantPatientsPersonsPhasePlacebosPlasmaPlasma SerumPlasminogenPlateletsPopulationPrevalencePreventative therapyPrevention trialPreventivePreventive therapyPrimary PreventionProbabilityProfibrinolysinProprotein ConvertasesProspective, cohort studyRandom AllocationRandom SelectionRandomization trialRandomizedRecording of previous eventsResearchResearch PersonnelResearch ResourcesResearchersResourcesReticuloendothelial System, Serum, PlasmaRiskRisk FactorsRoleSamplingSecondary PreventionSham TreatmentSingle Base PolymorphismSingle Nucleotide PolymorphismSocietiesSpecific qualifier valueSpecifiedSubgroupSubtilisinsTestingTherapeuticThrombocytesThrombosisTrainingUnited StatesWomanWomen's HealthWorkadvanced ageantisense oligoapo-B-100apoB-100apolipoprotein B-100apolipoprotein Lp(a+)apolipoprotein(a)atherogenesisatheromatosisatherosclerotic diseaseatherosclerotic vascular diseasebeta-Lipoproteinsblood losscardiac disease preventioncardiovascular disease preventioncardiovascular disease riskcardiovascular disordercardiovascular disorder preventioncardiovascular disorder riskcardiovascular riskcardiovascular risk factorcareercareer developmentcirculatory systemclinical practiceclinical trial analysiscohortdiabetesdiabeticepidemiologicepidemiologicalethnic diversityethnically diverseexperiencegenetic analysisgenetic epidemiologic studygenetic epidemiologygeriatrichistoriesinhibitorlipid disordermRNAmulti-ethnicmultiethnicnovelparticlepatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypesplatelet functionpolymorphismpreservationprevention clinical trialprofessorprospectiverandomisationrandomizationrandomized trialrandomly assignedrisk stratificationrisk/benefit ratiosecondary analysissenior citizensham therapysingle nucleotide variantskillssocial rolestatisticsstratify riskthrombotic diseasethrombotic disordertoolvascular inflammation
Description preview
PROJECT SUMMARY / ABSTRACT
Lipoprotein(a) [Lp(a)] is a lipid-carrying particle that contributes significantly to cardiovascular disease risk when
at elevated levels (estimated 30% of the population), but has limited options for therapy, especially for primary
prevention. Anti-platelet therapy with aspirin has become controversial for the primary…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click